Conditions: Thyroid Cancer
Keywords: medullary thyroid cancer MTC hereditary medullary thyroid cancer thyroid cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 19
Healthy volunteers: no

Brief summary:
This will be a Phase II, open label study to establish the effect of once-daily oral doses of ZD6474 100mg in subjects with locally advanced or metastatic hereditary medullary thyroid cancer in whom no standard therapeutic option is available.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: ZD6474 (vandetanib)
Intervention descriptions: intervention 1: 100 mg once daily oral tablet

Protocol document: